The validation of the Dutch SF-Qualiveen, a questionnaire on urinary-specific quality of life, in spinal cord injury patients by Reuvers-Verhoef, S.H.M. (Sarah) et al.
RESEARCH ARTICLE Open Access
The validation of the Dutch SF-Qualiveen, a
questionnaire on urinary-specific quality of
life, in spinal cord injury patients
Sarah H. M. Reuvers1*, Ida J. Korfage2, Jeroen R. Scheepe1, Lisette A. ‘t Hoen1, Tebbe A. R. Sluis3
and Bertil F. M. Blok1
Abstract
Background: Optimizing the patients’ quality of life is one of the main goals in the urological management of
spinal cord injury (SCI) patients. In this study we validated the Dutch SF-Qualiveen, a short questionnaire that
measures the urinary-specific quality of life, in SCI patients. No such measure is yet available for this patient group.
Methods: In 2015–2016 SCI patients with urinary symptomatology who visited the outpatient clinics of Urology at
the Erasmus Medical Centre and Rehabilitation at Rijndam Revalidation completed the SF-Qualiveen and UDI-6
during the visit and 1–2 weeks later. The UDI-6, a urinary tract symptom inventory, served as gold standard.
Controls, recruited from the Otolaryngology outpatient clinic, completed the questionnaires once. Content-,
construct-, and criterion validity and reliability (internal consistency and reproducibility) of the SF-Qualiveen were
determined.
Results: Fifty seven SCI patients and 50 controls were included. 12 SCI patients asserted that the SF-Qualiveen
covered their bladder problems (good content validity). Patients’ SF-Qualiveen scores being positively associated
with severity of urinary symptoms and patients’ scores being higher than those of controls indicated good
construct validity. The positive association that was found between SF-Qualiveen and UDI-6 in patients (r = 0.66–0.
67, P < 0.001) and controls (r = 0.63, P < 0.001) confirmed good criterion validity. Internal consistency (Cronbach’s
alpha 0.89–0.92) and reproducibility (intraclass correlation coefficient 0.94) of the SF-Qualiveen were good.
Conclusions: The Dutch SF-Qualiveen is a valid and reliable tool to measure the urinary-specific quality of life in SCI
patients.
Keywords: Patient reported outcome measure, Urinary bladder, neurogenic, Validation studies, Quality of life,
Surveys and questionnaires
Background
Spinal cord injury (SCI) causes urological dysfunction in
70–84% of patients [1]. The type of detrusor and/or
sphincter dysfunction depends on the localization of the
SCI and the damage to the spinal cord. Clinical presen-
tation can vary from urinary incontinence to inability to
empty the bladder [2].
More than two thirds of SCI patients in the
Netherlands reported bladder regulation problems as
one of their most frequent health problems [3]. Bladder
problems were perceived as a major secondary impair-
ment and as having the greatest impact on social life [3].
Bladder problems in patients with SCI were found to be
associated with a lower quality of life [4]. Optimizing the
quality of life is considered one of the most important
aspects in the urological management of patients with
neuro-urological dysfunction due to SCI [5].
Currently, there is no validated measure available in the
Netherlands to evaluate the urinary-specific quality of life
in SCI patients. The Qualiveen-30 [6] and its short version,
the SF-Qualiveen [7], are measures that evaluate urinary-
specific quality of life in patients with neurological
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disorders. The Qualiveen-30 has been validated in both
multiple sclerosis (MS) and SCI patients [6, 8], but is not
available in Dutch. Based on data of MS patients only, the
eight most responsive items of the Qualiveen-30 were used
to create the SF-Qualiveen [7]. The SF-Qualiveen has been
validated in English [7], French [7] and Dutch [9] for MS
patients, but not yet for SCI patients. Although the neuro-
urological dysfunction in MS and SCI patients is similar in
some aspects, its clinical presentation and the influence on
the quality of life might differ due to dissimilarities be-
tween the two diseases (e.g. the onset of disease is acute in
SCI vs. progressive in MS; SCI often entails a total loss of
sensation of the lower body, while MS entails an altered
sensibility, but often no total loss of sensibility). For this
reason, it is essential to evaluate the validity and reliability
of the SF-Qualiveen in SCI patients before its use can be
recommended as a measurement tool in the management
of Dutch SCI patients to optimize their quality of life.
Methods
Design and subjects
The research protocol (MEC-2014-534) was reviewed by
the local medical research ethics committee, which con-
cluded that the rules as stated in the Dutch Medical Re-
search Involving Human Subjects Act did not apply to
this study. The study was conducted at the Urology out-
patient clinic of the Erasmus University Medical Center
(Erasmus MC), Rotterdam, the Netherlands and at the
Rehabilitation outpatient clinic at Rijndam Rehabilita-
tion, Rotterdam, the Netherlands. In August and
September 2015 face-to-face interviews were conducted
with SCI patients with urinary symptomatology to assess
content-validity of the Dutch translated version of the
SF-Qualiveen. Between late September 2015 and May
2016 adult patients with SCI and urinary symptomatol-
ogy were included. We intended to invite all eligible
consecutive patients who visited the outpatients clinics
to participate. Exclusion criteria were cognitive impair-
ment, Dutch language difficulties, recent malignant
tumors, symptomatic urinary tract infections, and (fore-
seen) change of (bladder-specific) treatment within the
test-retest period. After having provided written
informed consent, participants completed the SF-
Qualiveen and the Urinary Distress Inventory-6 (UDI-6)
at the outpatient clinic (test) and 1 to 2 weeks later at
home (re-test). Clinical characteristics of included pa-
tients were retrieved from their medical charts.
We used earlier collected data of a control group,
that was recruited at the Otolaryngology outpatient
clinic in 2016 [9]. Exclusion criteria for this group
were cognitive impairment, Dutch language difficulties
and neuro-urological dysfunction. The control pa-
tients had provided written informed consent and
completed the measures once.
Measures
The SF-Qualiveen is a measure that evaluates the
urinary-specific quality of life in neuro-urological pa-
tients. Table 1 shows the eight questions of the question-
naire. Each item is scored on an ordinal Likert scale
ranging from 0 (no impact) to 4 (high impact). The total
score is the mean of the eight separate scores [7]. The
SF-Qualiveen consists of four domains, each containing
two questions: bother with limitations (question 1 and
2), fears (question 3 and 4), feelings (question 5 and 6)
and frequency of limitations (question 7 and 8).
The Dutch UDI-6 is a validated Dutch measure [10],
but has not been specifically validated in a neuro-
urological patient group. The questionnaire (six ques-
tions) assesses the severity of urinary tract symptoms. It
consists of three domains: irritative, stress and obstruct-
ive/discomfort urinary symptoms [11]. We chose this
measure as a gold standard in the absence of a perfect
gold standard for this patient group.
Validation process
The cross-cultural adaptation of the SF-Qualiveen into
Dutch by our group was previously described [9]. In
short; two forward-translations of the SF-Qualiveen from
English to Dutch, and one backward translation were
followed by consensus meetings between translators and
clinicians. Standardized guidelines for linguistic valid-
ation were followed [12]. Content validity was assessed
by face-to-face interviews with SCI and MS patients
[13]. The goal of these interviews was to confirm that
the translated version of the SF-Qualiveen used clear
wording and that it was a complete measure.
In the current study, predefined hypotheses on
construct validity were assessed:
1. We hypothesized that SF-Qualiveen scores of patients
would be positively associated with the severity of
urinary symptoms (UDI-6 domains irritative, stress
and obstructive/discomfort urinary symptoms and
total score).
Table 1 Questions of the SF-Qualiveen
1. In general, do your bladder problems complicate your life?
2. Are you bothered by the time spent passing urine or realizing
catheterization?
3. Do you worry about your bladder problems worsening?
4. Do you worry about smelling of urine?
5. Do you feel worried because of your bladder problems?
6. Do you feel embarrassed because of your bladder problems?
7. Is your life regulated by your bladder problems?
8. Can you go out without planning anything in advance?
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2. We hypothesized that scores of the SF-Qualiveen in
the patient group would be higher than scores in the
control group.
Criterion validity was determined by assessing the re-
lationship between the SF-Qualiveen and the UDI-6 as a
gold standard. Floor and ceiling effects were presumed to
be present if more than 15% of respondents achieved the
highest or lowest possible score. Therefore, percentages
of respondents with the highest and lowest possible
score were calculated. A floor effect was to be expected
in the control group.
The internal consistency of the SF-Qualiveen ques-
tions, i.e. whether the questions measure the same
underlying construct, was determined by calculating
Cronbach’s alpha. The reproducibility of the SF-
Qualiveen was determined by calculating the intraclass
correlation coefficient (ICC) for agreement of the re-
peated measurements. The limits of agreement (LOA)
were determined. In general, differences in scores within
the LOA can be interpreted as measurement error [14].
A post hoc subgroup analysis was performed to inves-
tigate construct- and criterion validity, internal
consistency and reproducibility of the Dutch SF-
Qualiveen in different subgroups based on level of SCI,
ASIA (American Spinal Injury Association) Impairment
Scale and manner of bladder emptying.
Statistical analyses
We aimed to include at least 50 patients and 50 controls
to comply with the guidelines for validation of question-
naires [13]. For the face-to-face interviews we aimed to
include at least 10 SCI patients.
For the statistical analyses we used SPSS version 21.
Descriptive results are presented as mean ± standard de-
viations for continuous data and counts and percentages
for discrete data. Student’s T-tests were used to assess
differences between groups for continuous variables and
Chi-Square tests for categorical variables. Associations
between variables were assessed using the Pearson’s cor-
relation coefficient in case of a linear association. Cron-
bach’s alpha’s were calculated to determine the internal
consistency. Cronbach’s alpha’s between 0.7 and 0.95
were considered good [13]. The LOA were calculated as
the mean change in scores of repeated measurements
±1.96 x standard deviation (SD) of the changes [14].
ICCs of 0.7 or higher were considered to represent good
reproducibility [13]. Statistical significance was assumed
at a p-value of less than 0.05.
Results
66 SCI patients completed the questionnaires at baseline
(‘test’). Seven patients did not return the second ques-
tionnaires while one declined further participation. The
mean SF-Qualiveen score (test) of these patients was
1.81 ± 0.65. One patient was diagnosed with a malignant
tumor and excluded. In total, 57 SCI patients completed
the second questionnaires (retest) on average 12.7 (±9.0)
days after the first questionnaires and were included in
the analyses. Characteristics of the study groups are dis-
played in Table 2. Most patients had a thoracic SCI, re-
quired a wheelchair for mobility and were dependent
upon catheterization (intermittent or indwelling) to
empty their bladder. The 50 controls were significantly
younger than the SCI patients. The proportion of males
and females was similar in both groups.
Validation process
Following the translation of the SF-Qualiveen into
Dutch, 12 SCI patients and 11 MS patients were inter-
viewed to assess content validity. The translated SF-
Qualiveen was distributed to the patients. Thereafter, pa-
tients were asked whether the questions covered all the
bladder problems that affected their quality of life. Both
patient groups agreed on the importance of the ques-
tions and found it a complete measure that covered the
broad range of bladder problems that they experienced.
Furthermore, patients found the Dutch version clear and
easy to complete.
The predefined hypotheses on construct validity were
confirmed:
1. Positive significant associations were found between
both the total UDI-6 and the different domains of
the UDI-6 which measure the severity of irritative,
stress and obstructive/discomfort urinary symptoms
and the total SF-Qualiveen scores in the patient
group. (Table 3) The hypothesis that SF-Qualiveen
scores of patients would be positively associated with
the severity of urinary symptoms was confirmed.
2. The mean of the total scores of the SF-Qualiveen for
the patient group was 1.81 ± 0.99 for the test and
1.80 ± 1.08 for the re-test while the control group
reported a mean score of 0.34 ± 0.59 (P < 0.001). In
an older subgroup of controls >40 years (n = 27,
mean age 53.9 years) the mean total SF-Qualiveen
score was 0.51. A significant difference in mean SF-
Qualiveen scores between the patient group and the
control group >40 years was found (P < 0.001).
A significant positive association between the SF-
Qualiveen and the UDI-6 was found in both the patient
(Table 3) and control group (r = 0.632 and P < 0.001).
Criterion validity was hereby found to be good. Floor
and ceiling effects were not found in the patient group
for the total SF-Qualiveen score (Test: no patients had
the lowest or highest possible score. Re-test: 2% of the
patients had the lowest and 2% had the highest possible
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score). As expected, a floor effect was found in the con-
trol group for the total SF-Qualiveen score: 50% of the
controls had the lowest possible score. No ceiling effect
was found in the control group (none had the highest
possible score).
Cronbach’s alpha’s of 0.89 (test) and 0.92 (re-test) indi-
cated good internal consistency for the total SF-
Qualiveen. (Table 4) The domains ‘bother with limita-
tions’ and ‘feeling’ showed good internal consistency as
well. Internal consistency of the domains ‘fears’ and ‘fre-
quency of limitations’ was moderate. The ICCs for the
repeated measurements of the test and re-test for the
SF-Qualiveen total score and domain scores showed
good reproducibility (Table 5). Table 5 shows the limits
of agreement (LOA) as well. Differences between −0.72
and 0.70 can be interpreted as not clinically important.
In Table 6 the results of the post hoc subgroup ana-
lyses based on level of SCI, ASIA Impairment Scale and
manner of bladder emptying are shown. Most subgroups
showed a positive significant association between the
SF-Qualiveen total scores and the UDI-6 score and a sig-
nificant difference in mean SF-Qualiveen scores com-
pared to the control group, indicating good criterion
and construct validity. Cronbach’s alpha’s of >0.79 and
Table 3 Correlations between severity of urinary symptoms (UDI-6 domain scores) – and SF-Qualiveen total scores in patient group
Test Re-test
UDI-6 – total score r = 0.663 and P < 0.001 r = 0.673 and P < 0.001
Severity of irritative urinary symptoms r = 0.596 and P < 0.001 r = 0.543 and P < 0.001
Severity of stress urinary symptoms r = 0.451 and P < 0.001 r = 0.424 and P = 0.001
Severity of obstructive/discomfort urinary symptoms r = 0.521 and P < 0.001 r = 0.630 and P < 0.001
Pearson’s correlation coefficients were determined to assess the relationship between variables. UDI-6, Urinary Distress Inventory-6
Table 2 Clinical characteristics
Patients Controls P-value
N 57 50
Age at examination 53.2 ± 14.6 42.3 ± 14.2 <0.001
Sex Male 37 (64.9%) 26 (52.0%) 0.176
Female 20 (35.1%) 24 (48.0%)
Years after SCI 13.1 ± 12.8
Level of SCI Cervical 15 (26.3%)
Thoracic 31 (54.4%)
Lumbar 11 (19.3%)
ASIA Impairment Scale A 23 (40.3%)
B 5 (8.8%)
C 7 (12.3%)
D 20 (35.1%)
Missing: 2 (3.5%)
Mobility Fully ambulatory 4 (7.0%)
Limited walking 16 (28.1%)
Wheelchair only 35 (61.4%)
Missing: 2 (3.5%)
Manner of bladder emptying (normal) voiding 5 (8.8%)
Abdominal pressure 1 (1.8%)
Total incontinence 1 (1.8%)
Intermittent catheterization 27 (47.4%)
Indwelling catheter 22 (38.6%)
Missing: 1 (1.8%)
Results are presented as mean ± standard deviations for continuous data and counts and percentages for discrete data. ASIA Impairment Scale, American Spinal
Injury Association Impairment Scale (A: Complete, B: Sensory incomplete, C: Motor incomplete - half of key muscle functions below the neurological level of injury
have a muscle grade less than 3, D: Motor incomplete - at least half of key muscle functions below the neurological level of injury have a muscle grade > 3) [16];
SCI, Spinal Cord Injury
Reuvers et al. BMC Urology  (2017) 17:88 Page 4 of 7
ICCs >0.86 confirmed good internal consistency and re-
producibility for the different subgroups.
Discussion
In this study we introduced the SF-Qualiveen in a SCI
patient group. We showed good content-, construct- and
criterion validity, internal consistency and reproducibil-
ity of the SF-Qualiveen in this patient group. We con-
clude that the SF-Qualiveen can be used in the
Netherlands to evaluate the urinary-specific quality of
life in SCI patients.
The ICCs of the repeated measurements in this study
(ranging from 0.79 to 0.94) showed good reproducibility
for the total SF-Qualiveen and the separate domains, al-
though they were somewhat lower than the ICCs found
in the French and English SF-Qualiveen validation study
in MS patients (0.88 to 0.94) [7]. The ICCs as found in
the present study are comparable to the Dutch valid-
ation study of the SF-Qualiveen in MS patients (0.72 to
0.90) [9]. The Dutch SF-Qualiveen showed to be a reli-
able instrument for SCI patients.
Internal consistency for the total SF-Qualiveen was
good. Cronbach’s alpha’s of 0.53 to 0.75 for the separate
domains ‘fears’ and ‘frequency of limitations’ showed
moderate internal consistency. This is consistent with
results from the Dutch validation study of the SF-
Qualiveen in MS patients [9]. Internal consistency was
not described in the French and English validation study
of the SF-Qualiveen. These study results indicate that
the four domains of the Qualiveen-30 cannot be con-
firmed in the SF-Qualiveen, probably due to the small
number of questions (two) in every domain. This
strengthens the previous recommendation of Reuvers et
al. [9] to not use the separate domains of the SF-
Qualiveen, but only the total SF-Qualiveen.
The results of the subgroup analyses suggest that the
Dutch SF-Qualiveen has equal measurement properties
for SCI patients with different levels of SCI, ASIA Im-
pairment statuses and manners of bladder emptying.
Not finding a statistical significant correlation between
the SF-Qualiveen scores and UDI-6 scores in the ASIA
group B (n = 5) and C (n = 7) and the group without
catheter usage (n = 7) could be explained by the lack of
statistical power in the small patient groups due to the
post hoc analysis.
Most SCI patients experience bladder problems as a
consequence of damage to the spinal cord [1, 3]. These
bladder problems have a negative effect on patients’
quality of life [4]. In the urological management of SCI
patients optimization of the quality of life is an import-
ant aspect as mentioned in the EAU guidelines [5].
Therefore, it is essential for healthcare professionals to
be informed about a patients’ present urinary-specific
quality of life. The SF-Qualiveen is now available to ob-
jectively assess this topic in the Dutch SCI population.
Only after being informed about present urinary-specific
quality of life, an optimal treatment plan can be defined.
For the future we suggest that urology and rehabilita-
tion departments in the Netherlands implement the
Dutch-version SF-Qualiveen in the urological manage-
ment of SCI patients. The Dutch SF-Qualiveen is now
available as a measurement tool. Further research should
be aimed at determining its responsiveness to treatment.
Once this has been established as sufficient, the Dutch
SF-Qualiveen may be used to evaluate the effect of treat-
ments on the urinary-specific quality of life in clinical
and research settings.
A question that arises is if we can recommend the use
of the SF-Qualiveen in all neuro-urological patients.
D’Ancona et al. [15] included, next to 33 SCI and eight
MS patients, 10 patients with meningomyelocele (MMC)
in the validation study of the Portuguese Qualiveen-30.
Results of the different patient groups were not separ-
ately described. The authors state that MMC patients
would have the same concerns regarding urinary-specific
quality of life as SCI and MS patients. However, there
might be a difference in the experience of patients with
congenital neurological diseases such as MMC com-
pared to patients with acquired diseases like SCI and
MS. Therefore, it would be valuable to study the useful-
ness of the SF-Qualiveen in congenital neurological
patients.
It is questionable if our Dutch version SF-Qualiveen
validated in the Netherlands can be used in other Dutch
speaking countries such as Belgium and South-Africa.
Although the language is technically the same, wording
and expressions can be different as well as cultural
Table 4 Internal consistency – Cronbach’s alpha (n = 57 SCI patients)
Test Re-test
SF-Qualiveen total score 0.89 0.92
SF-Qualiveen domains:
Bother with limitations 0.87 0.90
Fears 0.53 0.73
Feeling 0.80 0.84
Frequency of limitations 0.55 0.75
SCI Spinal Cord Injury
Table 5 Reproducibility of SF-Qualiveen
ICC LOA
SF-Qualiveen total score 0.94 −0.72 to 0.70
Bother with limitations 0.90 −1.12 to 1.00
Fears 0.92 −0.97 to 0.99
Feeling 0.87 −1.27 to 1.23
Frequency of limitations 0.79 −0.72 to 0.70
ICC Intraclass Correlation Coefficient, LOA Limits of Agreement
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habits. Therefore, we recommend a new validation
process before introducing the Dutch SF-Qualiveen in
other Dutch language countries.
A strength of this study was the homogeneous pa-
tient group of SCI patients. Study results therefore
provide a clear view of the validity and reliability of
the SF-Qualiveen in this patient group. Furthermore,
as this study was conducted at the outpatient clinics
of urology of a general hospital and rehabilitation
clinic, the SF-Qualiveen may be considered suitable
for the use in both settings.
A limitation of the study was that eight of 66 pa-
tients (12.1%) were excluded because they did not
complete the second questionnaire. This may have in-
troduced a selection bias. However, the SF-Qualiveen
scores (test) of these patients were similar to those of
the included patients. Therefore, the selection bias
may not be an important issue. Another limitation is
that no other validated urinary-specific quality of life
measure for neuro-urological patients is available to
serve as a perfect gold standard to determine the cri-
terion validity of the SF-Qualiveen. In the absence of
a perfect gold standard, we chose the UDI-6, a urin-
ary tract symptom inventory, which may have been
suboptimal. In addition, criticism could be raised on
the age difference between the patient and control
group. To investigate one of the hypotheses on
construct validity, we used data of a control group.
We hypothesized that scores of the SF-Qualiveen in
the patient group would be higher than scores in the
control group. As a consequence of using earlier col-
lected data, the age of the patient and control group
were not matched and we found a statistical signifi-
cant age difference between the groups. However, we
did not expect this age difference to influence out-
comes. We assumed that non-neuro-urological pa-
tients of the control group, regardless of their age,
would have lower scores on a measure that evaluates
the urinary-specific quality of life (developed for the
use in neuro-urological patients) than the neuro-
urological patient group. This expectation was
strengthened by the fact that we also found a statis-
tical significant difference in SF-Qualiveen scores be-
tween the patient group and the older control group
(>40 years).
Conclusions
From this study we can conclude that the Dutch SF-
Qualiveen is valid and reliable to measure the urinary-
specific quality of life in SCI patients. This short ques-
tionnaire, which is easy to complete, can be a valuable
instrument. We suggest to use the total Dutch SF-
Qualiveen for evaluation of the urinary-specific quality
of life in SCI patients.
Table 6 Subgroup analyses
Patient
numbers
Mean total
SF-Qualiveen
scores
Cronbach’s
alpha
ICC Correlation between
SF-Qualiveen scores
and UDI-6 scores
Patients’ SF-Qualiveen
scores compared to
controls
Level of SCI Cervical 15 (26%) 1.68–1.68 0.93–0.96 0.95 r = 0.853, p < 0.001
r = 0.788, p < 0.001
p < 0.001
Thoracic 31 (55%) 1.77–1.75 0.88–0.91 0.95 r = 0.552, p = 0.001
r = 0.547, p = 0.001
p < 0.001
Lumbar 11 (19%) 2.11–2.15 0.79–0.80 0.89 r = 0.686, p = 0.02
r = 0.769, p = 0.006
p < 0.001
ASIA Impairment
Scale
A 23 (40.3%) 1.58–1.50 0.88–0.92 0.94 r = 0.585, p = 0.003
r = 0.650, p = 0.001
p < 0.001
B 5 (8.8%) 2.18–2.48 0.80–0.88 0.92 r = 0.895, p = 0.040
r = 0.597, p = 0.287
p < 0.001
C 7 (12.3%) 1.70–1.57 0.83–0.82 0.86 r = 0.715, p = 0.071
r = 0.677, p = 0.095
p < 0.001
D 20 (35.1%) 2.04–2.11 0.90–0.92 0.96 r = 0.706, p < 0.001
r = 0.709, p < 0.001
p < 0.001
Missing: 2
Manner of bladder
emptying
No catheter use 7 (12%) 1.36–1.21 0.87–0.91 0.94 r = 0.707, p = 0.076
r = 0.817, p = 0.025
p < 0.001
Intermittent catheterization 27 (47%) 2.19–2.20 0.89–0.88 0.92 r = 0.571, p = 0.002
r = 0.518, p = 0.006
p < 0.001
Indwelling catheter 22 (39%) 1.47–1.48 0.85–0.93 0.95 r = 0.743, p < 0.001
r = 0.768, p < 0.001
p < 0.001
Missing: 1
ASIA Impairment Scale American Spinal Injury Association Impairment Scale, ICC Intraclass Correlation Coefficient
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